Anthelmintic drug discovery: target identification, screening methods and the role of open science

• Frederick A. Partridge,
• Ruth Forman,
• Carole J. R. Bataille,
• Graham M. Wynne,
• Marina Nick,
• Angela J. Russell,
• Kathryn J. Else and
• David B. Sattelle

Beilstein J. Org. Chem. 2020, 16, 1203–1224, doi:10.3762/bjoc.16.105

• been much progress in creating more potent and selective derivatives. This work exemplifies how open science approaches can catalyse drug discovery against neglected diseases. Keywords: anthelmintic; antiparasitic; cestode; nematode; trematode; Review The need for anthelmintic drug discovery

• different organisms, enabling researchers to identify and prioritise compounds active against multiple pathogens. For example MMV690102, which was originally developed as an inhibitor of kinetoplastid dihydrofolate reductase [159], is active against three trematode species (F. hepatica, S. haematobium, S

• selectivity compared to tolfenpyrad [131][170]. Praziquantel (5) Schistosomiasis is a major tropical disease resulting from the infection by a trematode parasite, the blood fluke Schistosoma mansoni [171]. After malaria, it is the next most devastating parasitic disease with millions affected worldwide. No